AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 284: E70-E75, 2003. First published September 3, 2002; doi:10.1152/ajpendo.00102.2002
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/1/E70    most recent
00102.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McHugh, N. A.
Right arrow Articles by Hey, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McHugh, N. A.
Right arrow Articles by Hey, J. A.
Vol. 284, Issue 1, E70-E75, January 2003

In vivo rat assay: bone remodeling and steroid effects on juvenile bone by pQCT quantification in 7 days

Nansie A. McHugh, Haydee M. Vercesi, Robert W. Egan, and John A. Hey

Allergy, Schering-Plough Research Institute, Kenilworth, New Jersey 07033

Anesthetized Sprague-Dawley weanling rats were scanned for bone mineral density (BMD) values after 7 days of treatment to determine whether resorption/growth at the proximal tibia can be quantified by peripheral quantitative computed tomography scanning techniques. Because the weanling rat is in a rapid growth stage, all groups showed significant increases in change from baseline values of BMD. Bisphosphonate treatment produced significant dose-related changes in BMD with average increases of 195 and 241% (10 and 20 µg/kg) vs. 86% in control rats. We further characterized this model to determine effects of steroids on growing bone. Graded doses of glucocorticoid (3.5, 7.0, 10.5, 14.0, 28.0, and 42.0 mg · kg-1 · wk-1) caused no significant differences in trabecular BMD in 7 days between control and treated rats. Significant decreases in growth (weights) and increases in cortical bone area were observed, indicating that this model may be useful in comparing effects of nonsteroid, anti-inflammatory alternatives on juvenile bone. Although the relevance of this model to adult disease remains to be elucidated, it also provides a tool for mechanistic evaluation of therapeutic modalities or efficacy assessment for dose selection for longerterm models.

osteoporosis; bone mineral density; glucocorticoid; computed tomography; animal model


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
N. A. McHugh, H. M. Vercesi, R. W. Egan, and J. A. Hey
Receptor activator of NF-{kappa}B ligand arrests bone growth and promotes cortical bone resorption in growing rats
J Appl Physiol, August 1, 2003; 95(2): 672 - 676.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online